vs
ISABELLA BANK CORP（ISBA）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是ISABELLA BANK CORP的1.4倍（$30.3M vs $21.2M），ISABELLA BANK CORP净利率更高（22.2% vs -221.3%，领先243.5%），REGENXBIO Inc.同比增速更快（43.0% vs 14.3%），ISABELLA BANK CORP自由现金流更多（$23.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 12.6%）
菲律宾群岛银行是菲律宾的全能型银行，同时也是菲律宾乃至整个东南亚历史最悠久的银行。按资产规模计算，它是菲律宾第四大银行；按市值计算则位列第二，是菲律宾盈利能力最强的银行之一。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ISBA vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.2M
营收增速更快
RGNX
高出28.7%
14.3%
净利率更高
ISBA
高出243.5%
-221.3%
自由现金流更多
ISBA
多$76.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
12.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.2M | $30.3M |
| 净利润 | $4.7M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 32.2% | -190.0% |
| 净利率 | 22.2% | -221.3% |
| 营收同比 | 14.3% | 43.0% |
| 净利润同比 | 17.4% | -31.2% |
| 每股收益（稀释后） | $0.64 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISBARGNX
| Q4 25 | $21.2M | $30.3M | ||
| Q3 25 | $20.5M | $29.7M | ||
| Q2 25 | $18.8M | $21.4M | ||
| Q1 25 | $18.1M | $89.0M | ||
| Q4 24 | $18.5M | $21.2M | ||
| Q3 24 | $18.0M | $24.2M | ||
| Q2 24 | $17.2M | $22.3M | ||
| Q1 24 | $16.7M | $15.6M |
净利润ISBARGNX
| Q4 25 | $4.7M | $-67.1M | ||
| Q3 25 | $5.2M | $-61.9M | ||
| Q2 25 | $5.0M | $-70.9M | ||
| Q1 25 | $3.9M | $6.1M | ||
| Q4 24 | $4.0M | $-51.2M | ||
| Q3 24 | $3.3M | $-59.6M | ||
| Q2 24 | $3.5M | $-53.0M | ||
| Q1 24 | $3.1M | $-63.3M |
毛利率ISBARGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ISBARGNX
| Q4 25 | 32.2% | -190.0% | ||
| Q3 25 | 30.7% | -176.3% | ||
| Q2 25 | 32.8% | -296.3% | ||
| Q1 25 | 26.9% | 13.6% | ||
| Q4 24 | 26.0% | -242.1% | ||
| Q3 24 | 21.3% | -256.6% | ||
| Q2 24 | 23.9% | -251.3% | ||
| Q1 24 | 21.8% | -408.8% |
净利率ISBARGNX
| Q4 25 | 22.2% | -221.3% | ||
| Q3 25 | 25.6% | -208.3% | ||
| Q2 25 | 26.7% | -331.8% | ||
| Q1 25 | 21.9% | 6.8% | ||
| Q4 24 | 21.6% | -241.3% | ||
| Q3 24 | 18.2% | -246.3% | ||
| Q2 24 | 20.3% | -237.7% | ||
| Q1 24 | 18.7% | -405.4% |
每股收益（稀释后）ISBARGNX
| Q4 25 | $0.64 | $-1.30 | ||
| Q3 25 | $0.71 | $-1.20 | ||
| Q2 25 | $0.68 | $-1.38 | ||
| Q1 25 | $0.53 | $0.12 | ||
| Q4 24 | $0.54 | $-0.99 | ||
| Q3 24 | $0.44 | $-1.17 | ||
| Q2 24 | $0.46 | $-1.05 | ||
| Q1 24 | $0.42 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $231.4M | $102.7M |
| 总资产 | $2.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ISBARGNX
| Q4 25 | $26.0M | $230.1M | ||
| Q3 25 | $161.3M | $274.2M | ||
| Q2 25 | $108.6M | $323.3M | ||
| Q1 25 | $69.2M | $267.9M | ||
| Q4 24 | $24.5M | $234.7M | ||
| Q3 24 | $27.4M | $255.5M | ||
| Q2 24 | $23.6M | $290.4M | ||
| Q1 24 | $25.2M | $338.7M |
股东权益ISBARGNX
| Q4 25 | $231.4M | $102.7M | ||
| Q3 25 | $227.4M | $161.5M | ||
| Q2 25 | $220.5M | $213.7M | ||
| Q1 25 | $215.6M | $274.2M | ||
| Q4 24 | $210.3M | $259.7M | ||
| Q3 24 | $213.0M | $301.4M | ||
| Q2 24 | $202.2M | $348.3M | ||
| Q1 24 | $200.7M | $390.7M |
总资产ISBARGNX
| Q4 25 | $2.2B | $453.0M | ||
| Q3 25 | $2.3B | $525.2M | ||
| Q2 25 | $2.2B | $581.0M | ||
| Q1 25 | $2.1B | $490.9M | ||
| Q4 24 | $2.1B | $466.0M | ||
| Q3 24 | $2.1B | $519.1M | ||
| Q2 24 | $2.1B | $569.4M | ||
| Q1 24 | $2.1B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $23.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 110.2% | -174.0% |
| 资本支出强度资本支出/营收 | 16.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.72× | — |
| 过去12个月自由现金流最近4个季度 | $36.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ISBARGNX
| Q4 25 | $26.8M | $-52.3M | ||
| Q3 25 | $2.7M | $-56.0M | ||
| Q2 25 | $7.8M | $-49.3M | ||
| Q1 25 | $4.7M | $33.6M | ||
| Q4 24 | $19.6M | $-31.6M | ||
| Q3 24 | $3.6M | $-40.5M | ||
| Q2 24 | $5.5M | $-45.5M | ||
| Q1 24 | $3.4M | $-55.5M |
自由现金流ISBARGNX
| Q4 25 | $23.3M | $-52.8M | ||
| Q3 25 | $1.7M | $-56.5M | ||
| Q2 25 | $7.2M | $-49.7M | ||
| Q1 25 | $3.7M | $32.6M | ||
| Q4 24 | $17.5M | $-32.7M | ||
| Q3 24 | $3.2M | $-40.9M | ||
| Q2 24 | $5.1M | $-46.0M | ||
| Q1 24 | $2.6M | $-56.0M |
自由现金流率ISBARGNX
| Q4 25 | 110.2% | -174.0% | ||
| Q3 25 | 8.5% | -189.9% | ||
| Q2 25 | 38.5% | -232.8% | ||
| Q1 25 | 20.6% | 36.6% | ||
| Q4 24 | 94.6% | -154.2% | ||
| Q3 24 | 17.7% | -168.9% | ||
| Q2 24 | 29.8% | -206.2% | ||
| Q1 24 | 15.7% | -358.5% |
资本支出强度ISBARGNX
| Q4 25 | 16.4% | 1.7% | ||
| Q3 25 | 5.0% | 1.7% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 5.5% | 1.2% | ||
| Q4 24 | 11.4% | 5.1% | ||
| Q3 24 | 2.0% | 1.3% | ||
| Q2 24 | 2.4% | 2.1% | ||
| Q1 24 | 4.9% | 3.6% |
现金转化率ISBARGNX
| Q4 25 | 5.72× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 1.56× | — | ||
| Q1 25 | 1.19× | 5.53× | ||
| Q4 24 | 4.91× | — | ||
| Q3 24 | 1.08× | — | ||
| Q2 24 | 1.59× | — | ||
| Q1 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISBA
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
